Tavotek Biotherapeutics

📢 Dr. Mark Chiu, PhD, will present a revolutionary approach to tackling EGFR inhibitor-resistant NSCLC using EGFR x cMET bispecific antibodies. Discover: 🔬 A process for selecting lead candidates with high functional activity. 🧪 In vitro cell-based assays for critical endpoint determination. 🎯 Strategies for designing bispecific formats targeting multiple therapeutic pathways. Don't miss this opportunity to delve into cutting-edge cancer treatment research and engage with our expert panelist during the live Q&A session. Register now and be a part of the future of oncology! 💡 #CancerResearch #LungCancer #BispecificAntibodies #OncologyInnovation #Webinar https://lnkd.in/gFDTKbJ8

Tavotek and David Brooks will be attending BIO 2024 in San Diego from June 3-6! Come chat with us to explore our latest biotherapeutic innovations. #BIO2024 #Tavotek Setup a meeting with us here --> https://lnkd.in/gcQVGJd4

We are thrilled to be featured in the latest GEN article on multispecific antibodies. Check out the full article to learn more about how we're making strides in the fight against cancer. https://lnkd.in/eeZ3N252

Thrilled to reflect on the insights gained from the BIONNOVA Beijing Innovation Forum 2024 and Festival of Biologics 2024, attended by our senior leadership. These conferences were invaluable for building global networks and sharing advancements in biotechnology. Excited to apply these innovative learnings to propel Tavotek forward. #Biotech #Innovation #Leadership #Networking #BIONNOVABeijing2024 #FestivalOfBiologics2024

🎉 Exciting News! Tavotek Biotherapeutics is thrilled to announce approval from Australia for our groundbreaking Phase 2 Trial featuring TAVO101, a best-in-class TSLP monoclonal antibody, targeting Severe Atopic Dermatitis!   🌏 Australia, known for its commitment to healthcare innovation, will be the starting point for our Phase 2 Trial. Tavotek Biotherapeutics is pioneering meaningful contributions to the field of biotherapeutics by providing relief and improving the quality of life for those affected by severe atopic dermatitis.   📈TAVO101 is a long-lasting TSLP antibody engineered with extended dosing ability for patient convenience. This trial is set to commence dosing in Q1 2024, this milestone underscores our dedication to advancing treatment options for patients globally.   We extend our heartfelt appreciation to the entire Tavotek team and our partners at HiRO - Harvest Integrated Research Organization, whose unwavering commitment has brought us to this pivotal moment. Together, we are pushing the boundaries of innovation to address the unique challenges posed by persistent health challenges.   #Tavotek #Biotechnology #TSLP #BiologicTherapy #AtopicDermatitis #Eczema #Dermatology

🚀Tavotek Biotherapeutics is thrilled to highlight Dr. Chao Han's interview in Clinical Pharmacology and Therapeutics by American Society of Clinical Pharmacology and Therapeutics. Dr. Han spoke about his time spearheading groundbreaking work at Tavotek in delivering RNA-based therapeutics into tumor cells.   🏆 Professional Achievement: Tavotek's innovative techniques show promising data, such as addressing "undruggable" intracellular targets in oncology.   🔬 Cutting-Edge Technology: Tavotek's focus on RNA-based therapeutics exhibit game-changer qualities in the quest for breakthrough oncology treatments. Congratulations to Dr. Han for being featured in ASCPT, we appreciate your thoughtful insights and skillful leadership! 🌐 Click here to read the full article: https://lnkd.in/e-xbwwyA #RNAtherapeutics #BiotechInnovation #OncologyBreakthroughs #UnmetMedicalNeeds #Tavotek

Tavotek Biotherapeutics is pleased to announce that our Chief Scientific Officer, Dr. Mark Chiu, will be showcased at the 23rd annual PepTalk Conference, happening from January 16-19, 2024, in San Diego, CA! His presentation is titled "1, 2, Bispecific Antibodies Do; 3, 4; Look Out for More; Driving Stronger Responses with Combinations of Bispecific Antibodies." This opportunity will delve into the future of biopharma, register now at CHI-peptalk.com! #PepTalkConference #BispecificAntibodies #PepTalk2024 #SanDiegoEvents #Tavotek

Introducing our speaker at 2023 #mAbTalk Symposium hosted by Chinese Antibody Society and its official journal, Antibody Therapeutics, on Sunday, December 17, 2023, Dr. Mark Chiu, CSO, Tavotek Biotherapeutics! His presentation's title will be "Attacking Solid Tumors of Unmet Medical Needs using Trispecific Abs". The conference will be in San Diego, CA. You are welcome to register the conference NOW at https://lnkd.in/gAG6Pp8J

Congratulations to Chao Han, our Vice President of Early Development, for being a featured panelist at the American Society of Clinical Pharmacology and Therapeutics! Join the discussion on Wednesday, Oct 4th, for an insightful discussion on the vital role of clinical pharmacologists and quantitative pharmacologists in developing cell and gene therapy (CGT). This session will spotlight innovative clinical pharmacology strategies to address the unique questions and challenges in translational PK/PD aspects of CGT. #ASCPT #ClinicalPharmacology #Pharmacology #Tavotek